BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Viatronix, Inc V3D(R)-Colon Platform Utilized for Key Laxative Free CT Colonography Trial


5/21/2012 11:46:20 AM

STONYBROOK, N.Y., May 21, 2012 /PRNewswire/ -- Viatronix Incorporated, a leading innovator and developer of 2D/3D medical imaging and diagnostic software today announced that their V3D®-Colon platform was exclusively used to perform a key study recently published in the Annals of Internal Medicine. The purpose of the study was to determine the feasibility of a laxative free bowel prep for patients undergoing a virtual colonoscopy (VC), screening exam. The trial utilized a modified version of the Viatronix V3D®-Colon software.

"The trial performed by the research group led by Dr. Michael Zalis at Massachusetts General Hospital demonstrates an option for a laxative free bowel prep and was visualized on the Viatronix V3D®-Colon platform," said Zaffar Hayat, CEO & President of Viatronix Incorporated. "CT Colonography (CTC), also known as virtual colonoscopy has been clinically proven over the past decade in multiple trials and is being adopted worldwide as a reliable alternative for colorectal cancer screening. Viatronix has been at the forefront of CTC research for many years and welcomes the scientific progress resulting from this study."

VC is now being reimbursed by insurance carriers in approximately 30 states within the U. S. Both the US House and Senate have introduced legislation that will require coverage of VC as a colon cancer screening benefit under Medicare. Adding CTC to the list of approved screening services will increase compliance with screening guidelines and has the potential to reduce unnecessary deaths from this cancer.

Every year over 50,000 Americans die from colorectal cancer in the U.S. and another 150,000 new cases of colorectal cancer are diagnosed. Colorectal Cancer is more than 90% preventable through early screening. Viatronix has been a leader in the field of virtual colonoscopy for over a decade and has supported research with a goal to provide the patients with a less invasive screening alternative.

About Viatronix

Viatronix, located in Stony Brook, New York, U.S.A. is a leading innovator of non-invasive 2D/3D medical imaging and diagnostic software that enables physicians to interactively view vital organs and anatomical structures within the human body. The Company 's V3D® technology software solutions include Viatronix V3D®-Colon, V3D®-Cardiac, V3D®-Vascular, V3D®-Calcium Scoring and V3D®-Explorer.

To learn more, call us at 1-866-887-4636 or visit: www.viatronix.com.

SOURCE Viatronix Incorporated



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES